Endocrine Therapy Combined with Targeted Therapy in Hormone Receptor-Positive Metastatic Breast Cancer

Did you know that about 70% of breast cancers are hormone receptor (HR)-positive—meaning they grow in response to estrogen or progesterone? For people with metastatic HR-positive breast cancer (MBC, where cancer has spread to other parts of the body), endocrine therapy (drugs that block hormone signals) has long been a cornerstone of treatment. But a major challenge remains: over time, many patients develop resistance—the therapy stops working. Today, a new era of “endocrine plus targeted therapy” is changing outcomes by pairing traditional endocrine drugs with precision medicines to overcome resistance and extend life. Let’s break down the latest science, based on research from Li Bian, Feng-Rui Xu, and Ze-Fei Jiang at the Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing.

The Evolution of Endocrine Therapy for Metastatic Breast Cancer

Endocrine therapy works by cutting off the “fuel” (estrogen/progesterone) that HR-positive cancers need to grow. For years, aromatase inhibitors (AIs) like anastrozole or letrozole were first-line treatments for postmenopausal women. But as more patients developed resistance, a newer drug—fulvestrant (a potent estrogen receptor blocker)—emerged as a game-changer.

Key studies backing fulvestrant:

The CONFIRM trial (2010, Journal of Clinical Oncology): Found that fulvestrant 500mg (a higher dose) significantly improved survival for postmenopausal women with advanced breast cancer compared to the 250mg dose.
The FIRST (2012, Breast Cancer Research and Treatment) and FALCON (2016, Lancet) trials: Showed fulvestrant 500mg worked better than anastrozole as a first-line treatment for postmenopausal MBC, with longer progression-free survival (PFS)—the time until cancer gets worse. For example, FALCON found median PFS was 16.6 months with fulvestrant vs. 13.8 months with anastrozole.

For premenopausal women (a group with high MBC rates in China), guidelines recommend suppressing ovarian function (with drugs like goserelin or surgery) before using endocrine therapy. The ongoing PROOF trial (phase II) is testing fulvestrant plus goserelin vs. anastrozole plus goserelin in Chinese premenopausal women—and early data suggests fulvestrant may be more effective.

Why Does Endocrine Therapy Stop Working?

Resistance happens when cancer cells find “workarounds” to grow without hormones. Common mechanisms include:

Overactive cell cycle pathways: The Cyclin D-CDK4/6-Rb pathway (which controls cell division) interacts with estrogen signals—cancer cells often “hijack” this to keep growing even when hormones are blocked.
Epigenetic changes: Enzymes called histone deacetylases (HDACs) alter how genes are expressed, making cancer cells resistant to endocrine therapy.
Mutations: Genes like ESR1 (estrogen receptor) or PIK3CA (which drives cell growth) can mutate, letting cancer grow independently of hormones.
Other pathways: The PI3K-AKT-mTOR pathway (another cell growth driver) is often overactive in resistant cancers.

Targeted therapies aim to block these “escape routes,” restoring sensitivity to endocrine therapy.

The “Endocrine Plus” Revolution: Targeted Drugs That Work

Researchers have focused on three key classes of targeted drugs—all shown in trials to boost the power of endocrine therapy.

1. CDK4/6 Inhibitors: The First Breakthrough

CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) block the Cyclin D-CDK4/6-Rb pathway, stopping cancer cells from dividing. When paired with endocrine therapy, they create a “double hit” on HR-positive cancers.

Key Trials:

PALOMA-2 (2016, New England Journal of Medicine): Postmenopausal women using letrozole (an AI) plus palbociclib had a median PFS of 27.6 months—more than double the 14.5 months with letrozole alone.
MONALEESA-7 (2018, Lancet Oncology): For premenopausal women, ribociclib plus endocrine therapy (tamoxifen or an AI) and ovarian suppression extended median PFS to 23.8 months vs. 13 months with placebo. Later results (2019 ASCO Meeting) showed a 29% lower risk of death (longer overall survival, OS).
MONARCH-2 (2017, Journal of Clinical Oncology): Abemaciclib plus fulvestrant doubled median PFS for postmenopausal women with AI-resistant MBC (16.4 months vs. 9.3 months with fulvestrant alone).
MONARCH Plus (China-led, 2020): Tested abemaciclib plus AIs (first-line) or fulvestrant (second-line) in Chinese patients. Interim results showed:
- Cohort A (first-line): Median PFS was not reached (still ongoing) with abemaciclib plus AI vs. 14.7 months with AI alone.
- Cohort B (AI-resistant): Median PFS was 11.4 months with abemaciclib plus fulvestrant vs. 5.6 months with fulvestrant alone.

These drugs are now FDA and NMPA-approved for HR-positive MBC, making them a standard of care.

2. HDAC Inhibitors: Fixing Epigenetic Resistance

HDAC inhibitors like tucidinostat (China-developed) reverse epigenetic changes that cause resistance. The ACE trial (2019, Lancet Oncology) tested tucidinostat plus exemestane (a steroidal AI) in postmenopausal women who had failed tamoxifen or AIs. Results:

Median PFS: 7.4 months vs. 3.8 months with exemestane alone.
Clinical Benefit Rate (CBR): 46.7% vs. 35.5% (CBR includes patients with stable disease or tumor shrinkage for at least 6 months).

Tucidinostat is now approved in China for this patient group—offering a new option after AI resistance.

3. PI3K/AKT/mTOR Inhibitors: Blocking Growth Pathways

The PI3K-AKT-mTOR pathway is overactive in ~40% of HR-positive MBCs, especially those with PIK3CA mutations. Inhibitors targeting this pathway (e.g., alpelisib, everolimus) restore sensitivity to endocrine therapy.

Key Trials:

SOLAR-1 (2019, New England Journal of Medicine): For women with PIK3CA-mutated MBC, alpelisib plus fulvestrant extended median PFS to 11 months vs. 5.7 months with fulvestrant alone. Alpelisib is now FDA-approved for this subset.
BOLERO-2 (2012, New England Journal of Medicine): Everolimus (an mTOR inhibitor) plus exemestane more than doubled median PFS for AI-resistant patients (7.8 months vs. 3.2 months).

A newer drug—capivasertib (an AKT inhibitor)—showed promise in the FAKTION trial (2019 ASCO): For AI-resistant women, capivasertib plus fulvestrant extended median PFS to 10.3 months vs. 4.8 months with fulvestrant alone.

Other Targeted Therapies: Early but Promising

Researchers are testing drugs targeting FGFR (fibroblast growth factor receptor), IGF-1R (insulin-like growth factor receptor), and VEGFR (vascular endothelial growth factor receptor)—but results are mixed:

FGFR inhibitors: The dovitinib trial (2017, Breast Cancer Research) found that for women with FGF pathway-amplified tumors, dovitinib plus fulvestrant extended median PFS to 10.9 months vs. 5.5 months with placebo.
VEGFR inhibitors: The CALGB 40503 trial (2016, Journal of Clinical Oncology) found bevacizumab (a VEGF blocker) plus letrozole extended median PFS to 20.2 months vs. 15.6 months with letrozole alone—but no OS benefit.

What About HR-Positive, HER2-Positive Metastatic Breast Cancer?

Some HR-positive cancers also overexpress HER2 (a protein that drives growth). For these patients, combining endocrine therapy with anti-HER2 drugs (like trastuzumab or pertuzumab) works better than either alone:

TAnDEM trial (2009, Journal of Clinical Oncology): Trastuzumab plus anastrozole extended median PFS to 4.8 months vs. 2.4 months with anastrozole alone.
PERTAIN trial (2018, Journal of Clinical Oncology): Pertuzumab plus trastuzumab plus an AI extended median PFS to 18.9 months vs. 15.8 months with trastuzumab plus AI.
MonarcHER trial (2019 ESMO): For women who had failed anti-HER2 therapy, trastuzumab plus abemaciclib (CDK4/6 inhibitor) plus fulvestrant extended median PFS to 8.3 months vs. 5.7 months with trastuzumab plus chemotherapy.

What Does This Mean for Patients?

The “endocrine plus targeted therapy” era offers clear benefits:

Longer PFS/OS: Drugs like palbociclib or ribociclib double or triple the time until cancer progresses.
Less toxicity: Targeted therapies often have milder side effects than chemotherapy (e.g., fatigue, low blood counts vs. hair loss, nausea).
Personalized options: Biomarkers (like PIK3CA mutations or CDK4/6 pathway activity) help doctors choose the right drug for the right patient.

For example:

First-line (no prior endocrine therapy): Postmenopausal women can use an AI plus palbociclib/ribociclib/abemaciclib. Premenopausal women add ovarian suppression.
AI-resistant: Fulvestrant plus a CDK4/6 inhibitor or tucidinostat plus exemestane.
PIK3CA-mutated: Alpelisib plus fulvestrant.

The Future: Biomarkers and Beyond

The biggest challenge now is precision: identifying which patients will benefit most from each therapy. For example, the SAFIRTOR trial (2019 ASCO) found that patients with high p4EBP1 (a marker of mTOR pathway activity) lived longer on everolimus plus exemestane.

As more biomarkers are discovered, doctors will be able to tailor treatments even more—turning MBC from a terminal diagnosis into a manageable chronic condition.

Final Thoughts

For women with metastatic HR-positive breast cancer, the “endocrine plus” approach is a beacon of hope. Drugs like palbociclib, ribociclib, abemaciclib, and tucidinostat are already extending lives, and new trials are uncovering even more options. While resistance and side effects remain challenges, the combination of traditional endocrine therapy and precision medicine is changing what it means to live with MBC.

Based on research from Li Bian, Feng-Rui Xu, and Ze-Fei Jiang published in the Chinese Medical Journal (2020).

https://doi.org/10.1097/CM9.0000000000000923

Was this helpful?

0 / 0